Can the success with immunotherapy in metastatic urothelial bladder carcinoma be replicated in the neoadjuvant setting?

Immunotherapy. 2020 Dec;12(17):1209-1212. doi: 10.2217/imt-2020-0244. Epub 2020 Oct 29.

Authors

Fouad Aoun^{1

2}, Georges Mjaess², Elie Nemr², Simone Albisinni³, Thierry Roumeguere^{1

3}

Affiliations

¹ Department of Urology, Institut Jules Bordet, Brussels, Belgium.
² Department of Urology, Hotel-Dieu de France, University of Saint Joseph, Beirut, Lebanon.
³ Department of Urology, University Clinics of Brussels, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.

PMID: 33115304
DOI: 10.2217/imt-2020-0244

No abstract available

Keywords: circulating tumor cells; immune checkpoint inhibitors; immunotherapy; neoadjuvant; urothelial bladder carcinoma.

Publication types

Editorial

MeSH terms

Humans
Immunotherapy / methods*
Neoadjuvant Therapy / methods*
Treatment Outcome
Urinary Bladder Neoplasms / pathology*
Urinary Bladder Neoplasms / therapy*